Obicetrapib is advancing toward global launch, supported by strong phase III data, robust financials, and a differentiated clinical profile targeting LDL, HDL, Lp(a), and diabetes risk. Key trials (PREVAIL, REMBRANDT, RUBENS, SPINOZA) are on track, with regulatory milestones and commercial readines…
Obicetrapib is advancing as a differentiated CETP inhibitor with robust LDL and HDL effects, supported by strong clinical, genetic, and preclinical data. PREVAIL CVOT is on track, with interim analysis expected in early 2025, and commercial launch preparations are well underway in both the U.S. and…
Obicetrapib demonstrated strong LDL-C and biomarker reductions in Phase 3 trials, with a favorable safety profile and broad potential across cardiometabolic and neurodegenerative diseases. Regulatory progress and commercial readiness position the product for major US and EU launches, with key data…
NewAmsterdam Pharma received a positive CHMP opinion recommending EU marketing authorization for Ubeslo and Evlarco.Key Highlights:Original SEC Filing: NewAmsterdam Pharma Co N.V. [ NAMS ] - 8-K - Jul. 24, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important…
NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. NASDAQ:NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with…
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. NASDAQ:NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with…
(15:42 GMT) NewAmsterdam Pharma Price Target Raised to $51.00/Share From $47.00 by RBC Capital
